Related Experiment Video

Updated: Aug 14, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

S1PR3 inhibition impairs cell cycle checkpoint via the AKT/WEE1 pathway in oral squamous cell carcinoma

Xinxia Zhou1, Jinghao Liu1, Xu Chen1

  • 1Department of Clinical Immunology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.

Journal of Translational Medicine
|May 23, 2025
PubMed
Abstract

Insights

Sphingosine-1-phosphate receptor 3 (S1PR3) promotes oral cancer growth by disrupting the cell cycle. Targeting S1PR3 inhibits tumor progression and enhances cisplatin effectiveness in oral squamous cell carcinoma (OSCC) treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Sphingosine-1-phosphate receptor 3 (S1PR3) is implicated in various cancers.
  • Its specific role and mechanisms in oral squamous cell carcinoma (OSCC) are not well understood.

Purpose of the Study:

  • Investigate the function of S1PR3 in OSCC progression.
  • Evaluate S1PR3 as a potential therapeutic target for OSCC.

Main Methods:

  • Assessed S1PR3 expression using qPCR, Western blotting, IHC, and TCGA data.
  • Analyzed S1PR3's impact on OSCC proliferation, cell cycle, and prognosis.
  • Explored molecular mechanisms via RNA-seq and cell cycle arrays.
  • Tested combination therapy with an S1PR3 antagonist and cisplatin.

Main Results:

  • S1PR3 is overexpressed in OSCC, correlating with poor prognosis.
  • Targeting S1PR3 reduced AKT/WEE1/CDC2 phosphorylation, inhibiting cell cycle progression.
  • S1PR3 inhibition disrupted the G2/M checkpoint and suppressed OSCC proliferation.
  • Combined S1PR3 antagonist and cisplatin showed synergistic anti-tumor effects.

Conclusions:

  • S1PR3 critically regulates the OSCC cell cycle through the AKT/WEE1/CDC2 pathway.
  • S1PR3 represents a promising therapeutic target for OSCC treatment.
  • Combination therapy may enhance treatment efficacy for OSCC patients.
Keywords:
AKT signaling pathwayCell cycleOral squamous cell carcinomaSphingosine-1-phosphate receptor 3WEE1

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...